美国医改,研究报告.docVIP

美国医改,研究报告 ：美国 研究报告 医改 医改最新消息2016年 2016医改编制与薪酬 卫计委主任医改薪酬 篇一：美国医改相关论文中英文 Clinical Therapeutics/Volume 35, Number 4, 2013 Editor-in-Chief’s Note Health Care Reform Health care and health policy continue to be controversial domestic issues in the United States. Despite a slowingin the rate of growth of annual costs, most Americans feel that their budgets are strained by what they have to payfor health care, and most employers feel that their share of these costs for their employees is excessive. Currently, many Americans still do not have health care coverage. In an effort to remedy such concerns, a series of laws wereenacted in recent years. The first of these, the American Recovery and Reinvestment Act, was signed into law byPresident Obama in 2009. In 2010, after considerable conflict and disagreement, the Preservation of Access to Carefor Medicare Beneficiaries and Pension Relief Act became law. Also in 2010, the Patient Protection and AffordableCare Act and the Health Care and Education Reconciliation Act were signed into law. Although these new laws (taken together, they are often called Obamacare) should have a positive and beneficial impact on the health careof most Americans, there will be many challenges to these efforts as their provisions are phased in over the nextseveral years. Before we can have meaningful reforms, we must make improvements in our study designs and assessmentinstruments. Comparative effectiveness research (CER) is considered by many to be a key component of reform. However, there are limitations to analyses that use secondary databases and noandomized, controlled studies. Furthermore, how variables such as adherence, duration of exposure, and definitions, as well as types of outcomes, are handled can substantially affect the validity of CER. The articles by Campbell et al and Cohen in this issue arethoughtful commentaries on CER. These are among a collection of very scholarly reports in this issue assembled byour Topic Edi